HCA Healthcare reported Q3 2024 revenues of $17.487 billion, up from $16.213 billion in Q3 2023. Net income attributable to HCA rose to $1.270 billion, or $4.88 per diluted share, compared to $1.079 billion, or $3.91 per diluted share, in Q3 2023. Adjusted EBITDA increased to $3.267 billion from $2.880 billion year-over-year.Same facility admissions and equivalent admissions both increased 4.5% in Q3 2024. The company reaffirmed its 2024 guidance but noted results are likely to be in the lower half of the ranges due to hurricane impacts. HCA expects ongoing hurricane effects in Q4 2024 to impact earnings by $0.60 to $0.90 per share.HCA's Board declared a quarterly cash dividend of $0.66 per share, payable on December 27, 2024 to stockholders of record on December 13, 2024. The company also provided an initial positive outlook for 2025, expecting diluted EPS and Adjusted EBITDA growth near or slightly above its long-term growth ranges.

HCA Healthcare reported Q3 2024 revenues of $17.487 billion, up from $16.213 billion in Q3 2023. Net income attributable to HCA rose to $1.270 billion, or $4.88 per diluted share, compared to $1.079 billion, or $3.91 per diluted share, in Q3 2023. Adjusted EBITDA increased to $3.267 billion from $2.880 billion year-over-year.Same facility admissions and equivalent admissions both increased 4.5% in Q3 2024. The company reaffirmed its 2024 guidance but noted results are likely to be in the lower half of the ranges due to hurricane impacts. HCA expects ongoing hurricane effects in Q4 2024 to impact earnings by $0.60 to $0.90 per share.HCA's Board declared a quarterly cash dividend of $0.66 per share, payable on December 27, 2024 to stockholders of record on December 13, 2024. The company also provided an initial positive outlook for 2025, expecting diluted EPS and Adjusted EBITDA growth near or slightly above its long-term growth ranges.